Innovative Cellular Therapeutics Holdings Ltd's Form 4 filing
Lyell Immunopharma, Inc. (LYEL) · filed Jul 20, 2026
- Accession no.
- 0001140361-26-028955
- Filed
- Jul 20, 2026, 2:55 PM ET
- Trade date
- Jul 17, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $137. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Innovative Cellular Therapeutics Holdings LtdCIK 0002095697 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | Common Stock | SSaleDisposed | −10 | $13.70 | −$137 | 2,857,480 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.